Abstract

Minimally invasive surgery (MIS) has revolutionized the field of surgical oncology by offering patients less invasive treatment options with reduced recovery times and lower complication rates. This paper explores the intersection of MIS and tumor markers, focusing on CYFRA 21-1, tissue polypeptide specific antigen (TPS), neuron-specific enolase (NSE), and carcinoembryonic antigen (CEA). These tumor markers play crucial roles in the diagnosis, prognosis, and monitoring of various cancers, including lung, breast, colorectal, and neuroendocrine tumors. Integrating tumor marker analysis with MIS techniques enables clinicians to tailor treatment strategies, improve patient outcomes, and enhance overall cancer management. This review highlights the significance of combining advanced surgical approaches with molecular diagnostics, paving the way for personalized and precision medicine in oncology.